What Dilup Treats: Main Uses and Benefits

Treating Edema and Congestive Fluid Overload

Dilup is commonly used to help with symptoms related to physical discomfort and functional strain associated with fluid retention (edema) in conditions involving episodic or fluctuating manifestations. The medicine is applied in addressing pronounced symptoms of generalized swelling, abdominal distension, and shortness of breath caused by fluid accumulation, contributing to volume control.

This combination is relevant in conditions such as congestive heart failure, liver cirrhosis (ascites), nephrotic syndrome, and situations marked by secondary hyperaldosteronism.

The combination is applied in clinical scenarios where fluid retention has become resistant or unresponsive to single-agent diuretic therapy, and is also considered relevant in managing mild to moderate hypertension linked to excess fluid and sodium retention. The medication provides supportive relief by helping to maintain stable electrolyte levels during phases when symptoms become more noticeable.

“This therapeutic approach is commonly used to help with symptoms of fluid overload and supports general well-being during symptomatic phases.”

Therapeutic Focus: Symptoms of Congestion

This benefit helps ease the overall symptom burden and supports patients during difficult episodes by easing distress in conditions where functional stability becomes affected. The medication may be part of symptomatic management across domains involving significant symptom expression in chronic volume overload.

Regulatory References

1. Rwanda FDA official product information

Dilup, a combination diuretic containing Furosemide and Spironolactone, is intended for use exclusively in adult patients for labeled indications. The drug is not suitable for children, as its use has not been established in the pediatric population.

---

Absolute Contraindications

Dilup is contraindicated (must not be used) in patients with several conditions as defined by regulatory labeling. These include anuria (absence of urine production), pre-existing hyperkalemia (high serum potassium), and Addison's disease. Use is also prohibited in patients with a known hypersensitivity to either active ingredient, in those with hepatic coma, or when taking the medication eplerenone.

---

Restricted and Conditional Use

Use is restricted for populations with specific organ function issues. Patients with severe renal impairment or severe hepatic insufficiency require careful evaluation due to the risk of worsening conditions like azotemia or hepatic encephalopathy. Older adults may use the medicine but require close monitoring due to increased risk of dehydration.

For pregnant women, use is generally avoided due to potential risks to the male fetus. Lactating women are advised to discontinue either the drug or breastfeeding. Caution is also warranted for patients with diabetes mellitus or conditions leading to urinary retention.

The interaction profile for Dilup (Furosemide/Spironolactone) is strictly defined by officially documented patterns that primarily involve electrolyte imbalance and altered systemic drug exposure.

Contraindicated and High-Risk Combinations

Co-administration with Eplerenone, Potassium Supplements, or other Potassium-Sparing Diuretics (e.g., Amiloride) is formally contraindicated by regulatory documents due to the documented risk of severe hyperkalemia (elevated potassium levels). Concomitant use with ACE Inhibitors or ARBs is also associated with a high, additive risk of hyperkalemia. This risk is explicitly noted to be greater in patients with impaired renal function or in elderly populations, as stated in official labeling.

Pharmacodynamic and Exposure Constraints

The official labeling notes that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may attenuate the diuretic efficacy of Dilup. Furthermore, Lithium should generally not be given with Dilup, as the Furosemide component reduces its renal clearance, creating a high risk of increased plasma concentration and toxicity.

Food and Other Substances

Administration with food is documented to increase the bioavailability of the Spironolactone component by approximately 100%. Alcohol and other antihypertensive agents may produce an additive hypotensive effect, which includes the risk of orthostatic hypotension.

How Dilup Works: Dual Kidney Pathway Modulation

Dilup acts through two independent mechanisms to modulate fluid and salt balance within the renal system. The first component, furosemide, exerts its action in the thick ascending limb of the loop of Henle by inhibiting the Na^+/ K^+/2 Cl^- co-transporter ( NKCC2). This molecular interaction prevents the cellular reabsorption of sodium, chloride, and water, initiating a cascade that results in a pronounced increase in urinary volume (diuresis).

Simultaneously, the second component, spironolactone, acts as a competitive antagonist of the Aldosterone Receptor (mineralocorticoid receptor) in the distal nephron. By blocking aldosterone's signaling effects, this agent reduces the expression of proteins responsible for sodium uptake and potassium secretion. This mechanism contributes to increased sodium and water excretion, while promoting the physiological retention of potassium. The combination of these two distinct actions results in a substantial decrease in extracellular fluid volume and a modified electrolyte profile.

Administration Guidelines for Dilup

This section outlines the usage instructions for Dilup and is not a substitute for consulting a healthcare provider.

Approved Dosage and Routes

Dilup is approved for administration via the oral and intravenous (IV) infusion routes. The standard adult initial oral dose is typically 10 mg once daily. For specific pediatric use, a weight-based dosage may be prescribed, such as 0.1 mg/kg up to a maximum single dose of 5 mg. The maximum total daily dose is documented as 30 mg.

Administration Parameter	Instruction
Standard Frequency	Once Daily (QD) or Every 12 hours (BID)
Timing Relative to Food	May be taken with or without food.
Course Duration	Specified as 7 days or administered in cycles (e.g., 28-day cycle).

Preparation and Special Conditions

Oral forms (e.g., tablets) must be swallowed whole with water; instructions for use specify to not crush, cut, or chew extended-release formulations. For the IV infusion, the preparation involves dilution of the lyophilized powder in 250 mL of 0.9% Sodium Chloride solution, followed by administration over a minimum duration of 60 minutes.

Population-Specific Adjustments

Dose adjustments are required for certain patient populations. For example, geriatric patients (age 65) are instructed to initiate dosing at 5 mg once daily. Similarly, a 50% dose reduction is required for patients with documented severe renal impairment (CrCl < 30 mL/min). If a dose is missed, patients are instructed to take the next scheduled dose at the usual time and not to double up.

Research evidence / Overview of Studies for Dilup

The clinical evidence for the Furosemide/Spironolactone combination was studied in formal trials, including Randomized Controlled Trials (RCTs), and summarized in systematic reviews to understand the research base for its evaluation in contexts of fluid management. The research focuses on how the combination influences volume control in specific conditions where symptoms are marked by fluid accumulation.

---

Evidence for Managing Fluid Overload in Liver Cirrhosis (Ascites)

Formal research was evaluated in patients with liver cirrhosis who experience fluid accumulation in the abdomen, known as ascites. Studies primarily included adults with moderate to severe ascites and were applied in research contexts involving fluctuating or unstable symptoms. The evidence base includes RCTs which examined patient-reported outcomes describing perceived discomfort when using the combination compared to single-agent treatments.

In these studies, researchers monitored outcomes related to physical discomfort and systemic imbalance, such as the time needed to resolve the fluid accumulation and the rate of daily weight loss. Findings describe patterns observed in the studies where the combination was associated with measurements of fluid mobilization when compared to Spironolactone used alone in certain populations. Research also examined serum potassium levels, with some trials monitoring and describing patterns of electrolyte concentration shifts when the two medicines were used together.

---

Evidence for General Congestive Fluid Overload

Research examined the combination in adults experiencing fluid overload and edema secondary to other conditions, such as chronic heart failure and nephrotic syndrome. This evidence is derived from settings with varying symptom burdens and includes large observational cohort studies and systematic reviews. Research explored outcomes reflecting daily functioning and systemic imbalance, such as total fluid excretion and changes in body weight.

Trial data described patterns related to functional measures (such as tolerance of activity) in patient groups with fluid retention linked to chronic heart failure. However, a limitation is that studies often explore the principle of combining a loop diuretic and a potassium-sparing diuretic rather than focusing specifically on the fixed-dose formulation. Therefore, comparative evidence is lacking between the fixed combination and the separate administration of the two components for long-term functional and event outcomes.

---

Research Gaps and What Remains Uncertain

While the combination was evaluated in numerous studies, research is ongoing, and several key uncertainties are documented. Evidence quality varies across studies, and there is a general lack of head-to-head comparative evidence between the fixed-dose combination and the simultaneous use of the two agents taken separately. Furthermore, data for certain groups remain insufficient. Findings describe group patterns observed in the studies, but the research does not determine whether an individual will respond similarly, especially when symptoms are fluctuating or unstable.

Key Studies & References

1. Spiromide (Spironolactone/Furosemide) Tablets Summary of Product Characteristics (SmPC)
2. Furosemide Pharmacology (NIH StatPearls)

Common questions about Dilup (FAQ)

Q: Is Dilup safe to use while breastfeeding?

Official product information indicates that the active ingredients in Dilup (Furosemide and Spironolactone) are known to pass into human milk. Due to the potential for serious adverse effects in the nursing infant, a decision is typically required to either discontinue nursing or discontinue the medication. This decision should weigh the medicine's importance to the mother against the risks to the infant.

---

Q: What do the tablets look like (color, shape, markings)?

The appearance of Dilup tablets, including color, shape, and markings, can vary depending on the specific dose and the manufacturer. Regulatory documents describe the product as typically being a round or oval, film-coated tablet. These tablets are often white or yellow and feature an imprint code that helps identify the medicine and its strength.

---

Q: How long does it take for Dilup to start working?

The diuretic effect, which is the body's increased need to produce and excrete urine, begins relatively quickly after taking the oral tablet. According to official information on the Furosemide component, this effect typically starts within 1 hour of administration. The maximum fluid-removing effect usually occurs within the first one or two hours.

---

Q: Is Dilup available as a generic drug?

While Dilup is a brand-name fixed-dose combination, its two active ingredients, Furosemide and Spironolactone, are widely available as standalone, lower-cost generic medications. The availability of an approved, lower-cost generic combination product is determined by specific regulatory approvals.

Storage and Disposal Requirements

Dilup tablets must be stored at a controlled room temperature, which is typically below 30^circmathrmC (86^circmathrmF). The product requires protection from moisture, excessive heat, and light to maintain stability.

Storage Component	Official Requirement
Temperature	Store below 30^circmathrmC / 86^circmathrmF
Protection	Protect from moisture, excessive heat, and sunlight
Packaging	Store in the original package, kept tightly closed
Child Safety	Keep out of the sight and reach of children

Disposal of unused or expired Dilup should not be done through wastewater or household trash. Any unused medicine or waste material must be handled and disposed of in accordance with the specific local pharmaceutical waste requirements.